Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 67,950 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 67,950 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $0.47, for a total value of $31,936.50. Following the transaction, the director owned 763,685 shares of the company’s stock, valued at $358,931.95. This trade represents a 8.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total value of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.

Werewolf Therapeutics Trading Up 4.4%

Werewolf Therapeutics stock traded up $0.02 during midday trading on Tuesday, reaching $0.46. 797,900 shares of the stock traded hands, compared to its average volume of 465,332. The company has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.77. Werewolf Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $2.38. The firm has a market cap of $22.51 million, a PE ratio of -0.37 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth about $409,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics during the 3rd quarter worth about $304,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics has an average rating of “Hold” and an average price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.